Metastatic Cancer Pipeline Review, H1 2013


#164933

475pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Metastatic Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Cancer. 

Metastatic Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Cancer.
  • A review of the Metastatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 6
Metastatic Cancer Overview 7
Therapeutics Development 8
Metastatic Cancer Therapeutics under Development by Companies 10
Metastatic Cancer Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 21
Mid Clinical Stage Products 22
Early Clinical Stage Products 23
Discovery and Pre-Clinical Stage Products 24
Metastatic Cancer Therapeutics Products under Development by Companies 25
Metastatic Cancer Therapeutics Products under Investigation by Universities/Institutes 34
Companies Involved in Metastatic Cancer Therapeutics Development 38
Metastatic Cancer Therapeutics Assessment 105
Drug Profiles 112
Metastatic Cancer Therapeutics Drug Profile Updates 363
Metastatic Cancer Therapeutics Discontinued Products 439
Metastatic Cancer Therapeutics - Dormant Products 442
Metastatic Cancer Product Development Milestones 453

Appendix 459

Number of Products Under Development for Metastatic Cancer, H1 2013 23
Products under Development for Metastatic Cancer Comparative Analysis, H1 2013 24
Number of Products under Development by Companies, H1 2013 26
Number of Products under Development by Companies, H1 2013 (Contd..1) 27
Number of Products under Development by Companies, H1 2013 (Contd..2) 28
Number of Products under Development by Companies, H1 2013 (Contd..3) 29
Number of Products under Development by Companies, H1 2013 (Contd..4) 30
Number of Products under Development by Companies, H1 2013 (Contd..5) 31
Number of Products under Investigation by Universities/Institutes, H1 2013 33
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 34
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 35
Comparative Analysis by Late Stage Development, H1 2013 36
Comparative Analysis by Mid Clinical Stage Development, H1 2013 37
Comparative Analysis by Early Clinical Stage Development, H1 2013 38
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 39
Products under Development by Companies, H1 2013 40
Products under Development by Companies, H1 2013 (Contd..1) 41
Products under Development by Companies, H1 2013 (Contd..2) 42
Products under Development by Companies, H1 2013 (Contd..3) 43
Products under Development by Companies, H1 2013 (Contd..4) 44
Products under Development by Companies, H1 2013 (Contd..5) 45
Products under Development by Companies, H1 2013 (Contd..6) 46
Products under Development by Companies, H1 2013 (Contd..7) 47
Products under Development by Companies, H1 2013 (Contd..8) 48
Products under Investigation by Universities/Institutes, H1 2013 49
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 50
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 51
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 52
Bristol-Myers Squibb Company, H1 2013 53
Boehringer Ingelheim GmbH, H1 2013 54
F. Hoffmann-La Roche Ltd., H1 2013 55
Biogen Idec Inc., H1 2013 56
Amgen Inc., H1 2013 57
Sanofi-Aventis, H1 2013 58
AstraZeneca PLC, H1 2013 59
Eli Lilly and Company, H1 2013 60
Genentech, Inc., H1 2013 61
Daiichi Sankyo Company, Ltd, H1 2013 62
Merck & Co., Inc., H1 2013 63
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 64
Takeda Pharmaceutical Company Limited, H1 2013 65
Nanotherapeutics, Inc., H1 2013 66
ZIOPHARM Oncology, Inc., H1 2013 67
Novartis AG, H1 2013 68
Aphios Corporation, H1 2013 69
Astellas Pharma Inc., H1 2013 70
Chong Kun Dang Pharmaceutical, H1 2013 71
Eisai Co., Ltd., H1 2013 72
Ono Pharmaceutical Co., Ltd., H1 2013 73
Pfizer Inc., H1 2013 74
SuperGen, Inc., H1 2013 75
Cell Therapeutics, Inc., H1 2013 76
Exelixis, Inc., H1 2013 77
Celgene Corporation, H1 2013 78
Merck KGaA, H1 2013 79
EntreMed, Inc., H1 2013 80
Momenta Pharmaceuticals, Inc., H1 2013 81
AEterna Zentaris Inc., H1 2013 82
ARQULE, INC, H1 2013 83
Telik, Inc., H1 2013 84
Hanall Pharmaceutical Co., Ltd., H1 2013 85
Threshold Pharmaceuticals, Inc., H1 2013 86
Galapagos NV, H1 2013 87
Nang Kuang Pharmaceutical Co., Ltd., H1 2013 88
e-Therapeutics plc, H1 2013 89
Rexahn Pharmaceuticals, Inc., H1 2013 90
MabVax Therapeutics, Inc., H1 2013 91
Morphotek, Inc., H1 2013 92
Wilex AG, H1 2013 93
Actinium Pharmaceuticals, Inc., H1 2013 94
Nerviano Medical Sciences S.r.l., H1 2013 95
Glycotope GmbH, H1 2013 96
Curacyte AG, H1 2013 97
Altor BioScience Corporation, H1 2013 98
Provecs Medical GmbH, H1 2013 99
Alethia Biotherapeutics Inc., H1 2013 100
Five Prime Therapeutics, Inc., H1 2013 101
Merrimack Pharmaceuticals, Inc., H1 2013 102
Deciphera Pharmaceuticals, LLC, H1 2013 103
MSM Protein Technologies, Inc., H1 2013 104
Vascular Biogenics Ltd., H1 2013 105
Axelar AB, H1 2013 106
Cornerstone Pharmaceuticals, Inc., H1 2013 107
Advenchen Laboratories, LLC, H1 2013 108
Syndax Pharmaceuticals, Inc., H1 2013 109
Omeros Corporation, H1 2013 110
BIND Biosciences, Inc., H1 2013 111
PharmaMar, S.A., H1 2013 112
AmpliMed Corporation, H1 2013 113
Biothera, H1 2013 114
AVEO Pharmaceuticals, Inc., H1 2013 115
TRACON Pharmaceuticals, Inc., H1 2013 116
PharmAbcine, Inc., H1 2013 117
ECI, Inc., H1 2013 118
Gradalis Inc., H1 2013 119
Assessment by Monotherapy Products, H1 2013 120
Assessment by Combination Products, H1 2013 121
Assessment by Stage and Route of Administration, H1 2013 123
Assessment by Stage and Molecule Type, H1 2013 126
Metastatic Cancer Therapeutics Drug Profile Updates 378
Metastatic Cancer Therapeutics Discontinued Products 454
Metastatic Cancer Therapeutics Discontinued Products (Contd..1) 455
Metastatic Cancer Therapeutics Discontinued Products (Contd..2) 456
Metastatic Cancer Therapeutics Dormant Products 457
Metastatic Cancer Therapeutics Dormant Products (Contd..1) 458
Metastatic Cancer Therapeutics Dormant Products (Contd..2) 459
Metastatic Cancer Therapeutics Dormant Products (Contd..3) 460
Metastatic Cancer Therapeutics Dormant Products (Contd..4) 461
Metastatic Cancer Therapeutics Dormant Products (Contd..5) 462
Metastatic Cancer Therapeutics Dormant Products (Contd..6) 463
Metastatic Cancer Therapeutics Dormant Products (Contd..7) 464
Metastatic Cancer Therapeutics Dormant Products (Contd..8) 465
Metastatic Cancer Therapeutics Dormant Products (Contd..9) 466
Metastatic Cancer Therapeutics Dormant Products (Contd..10) 467
Number of Products under Development for Metastatic Cancer, H1 2013 23
Products under Development for Metastatic Cancer Comparative Analysis, H1 2013 24
Products under Development by Companies, H1 2013 25
Products under Investigation by Universities/Institutes, H1 2013 32
Late Stage Products, H1 2013 36
Mid Clinical Stage Products, H1 2013 37
Early Clinical Stage Products, H1 2013 38
Discovery and Pre-Clinical Stage Products, H1 2013 39
Assessment by Monotherapy Products, H1 2013 120
Assessment by Combination Products, H1 2013 121
Assessment by Route of Administration, H1 2013 122
Assessment by Stage and Route of Administration, H1 2013 123
Assessment by Molecule Type, H1 2013 124
Assessment by Stage and Molecule Type, H1 2013 125